Stockscreener 앱 받기
23.25
0.87%
0.20
시간 외 거래:
23.25
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
What is ACADIA Pharmaceuticals Inc. company’s growth strategyInvest confidently with daily market forecasts - jammulinksnews.com
What institutional investors are buying ACADIA Pharmaceuticals Inc. stockOutstanding stock performance - jammulinksnews.com
Is it the right time to buy ACADIA Pharmaceuticals Inc. stockGrow your portfolio with growth-oriented stocks - jammulinksnews.com
Is ACADIA Pharmaceuticals Inc. stock overvalued or undervaluedFree Trading Strategy Suggestions - jammulinksnews.com
Why ACADIA Pharmaceuticals Inc. stock attracts strong analyst attentionBreakout Momentum Stocks - Metal.it
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - 富途牛牛
What risks could impact ACADIA Pharmaceuticals Inc. stock performanceFree Investment Risk Control - jammulinksnews.com
Is ACADIA Pharmaceuticals Inc. a good long term investmentConsistent high-performance stocks - PrintWeekIndia
What drives ACADIA Pharmaceuticals Inc. stock priceHigh-yield portfolio picks - PrintWeekIndia
ACADIA Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - Autocar Professional
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025 - BioSpace
What analysts say about ACADIA Pharmaceuticals Inc. stockPowerful profit generation - Autocar Professional
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN
Bank of America Securities Sticks to Their Hold Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Acadia Debuts New Team, Pipeline With ‘Biotech Powerhouse’ Ambitions - BioSpace
What makes ACADIA Pharmaceuticals Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru
The $12 Billion Opportunity Bolstering This Biotech Stock - Investor's Business Daily
ACADIA Pharmaceuticals’ SWOT analysis: stock poised for growth amid pipeline expansion - Investing.com Australia
Acadia Pharmaceuticals Rides High On Patent Wins And Strong Pipeline - Finimize
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline - BioPharma Dive
ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Acadia Pharmaceuticals' Stocks Undervalue Future Blockbuster Potential - Finimize
ACAD: ACADIA Pharmaceuticals Receives Buy Rating from Needham | ACAD Stock News - GuruFocus
Stocks With Rising Composite Ratings: ACADIA Pharmaceuticals - Investor's Business Daily
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers - Business Wire
Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital - Yahoo Finance
13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know - Nasdaq
Learn to Evaluate (ACAD) using the Charts - news.stocktradersdaily.com
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent - MSN
ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years - Yahoo Finance
Bavarian Nordic sells priority review voucher to US healthcare system USD 160m - medwatch.com
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus
0.97%
0.22%
자본화:
|
볼륨(24시간):